1. Home
  2. ALAR vs MNOV Comparison

ALAR vs MNOV Comparison

Compare ALAR & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

HOLD

Current Price

$6.23

Market Cap

58.8M

Sector

Technology

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.44

Market Cap

66.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALAR
MNOV
Founded
2013
2000
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
66.9M
IPO Year
2018
2004

Fundamental Metrics

Financial Performance
Metric
ALAR
MNOV
Price
$6.23
$1.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$14.00
$7.50
AVG Volume (30 Days)
37.6K
50.6K
Earning Date
03-19-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
$33.30
N/A
Revenue Next Year
$30.53
N/A
P/E Ratio
$44.31
N/A
Revenue Growth
N/A
194.15
52 Week Low
$5.50
$1.17
52 Week High
$18.00
$1.96

Technical Indicators

Market Signals
Indicator
ALAR
MNOV
Relative Strength Index (RSI) 45.28 51.45
Support Level $5.50 $1.40
Resistance Level $7.76 $1.60
Average True Range (ATR) 0.42 0.06
MACD 0.04 0.01
Stochastic Oscillator 59.02 43.52

Price Performance

Historical Comparison
ALAR
MNOV

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: